甘精胰岛素及格列美脲对新诊断2型糖尿病患者血糖波动的影响

摘要

Objective To explore the effect of glargine combined with glimepiride on blood glucose variability irt newly diagnosed type 2 diabetic patients with HbA1c>9％. Methods Forty-six patients were randomized into two groups and treated with glargine plus glimepiride versus insulin aspart 30 respectively for 12 weeks. The daily blood glucose level was measured with the continuous glucose monitoring system and compared before and after intensive therapy between two groups. Results The blood glucose levels in both groups were well controlled. However, there was a more stable blood glucose profile, less hypoglycemia, and smaller insulin dosage in the group treated with glargine + glimepiride than in insulin aspart 30 group (P<0. 05). Conclusion Glimepiride combined with glargine is more convenient and safer, than insulin aspart 30 in the treatment of newly diagnosed type 2 diabetic patients with HbA1c>9%.%目的 探讨甘精胰岛素联合格列美脲及诺和锐30对HbA1c＞9％的新诊断T2DM患者血糖波动的影响. 方法 将46例新诊断的T2DM患者随机分为甘精胰岛素联合格列美脲(IG)组与诺和锐30(AS30)组.IG组予以睡前皮下注射甘精胰岛素联合口服格列美脲治疗12周；AS30组予以诺和锐30于早晚餐时皮下注射12周,对比两组治疗前后血糖谱的变化. 结果 IG组与AS30组血糖均得到效控制,但IG组血糖波动小、低血糖事件发生率低、胰岛素用量少(P＜0.05). 结论 甘精胰岛素联合格列美脲对HbA1c＞9％的新诊断T2DM患者是一种更为安全、方便的治疗方案.